| Author | Prior systemic therapy (yes vs. no) |
Radiation (within the previous 3 months) | Antibiotics (within the previous 2 months) | Age (years) (<65 vs. ≥65) |
PD-L1 (1%–49%) |
PD-L1 (>50%) |
Anti-PD(L)1 compound—nivolumab | Anti-PD(L)1 compound—pembrolizumab | Anti-PD(L)1 compound—atezolizumab |
|---|---|---|---|---|---|---|---|---|---|
| Umang Swami (11) | 0.94 [0.64, 1.36] p = 0.73 | 1.60 [1.00, 2.58] p = 0.05 |
1.28 [0.80, 2.04] p = 0.30 |
1.05 [0.93, 1.17] p = 0.46 |
NA | NA | NA | NA | NA |
| A. Cortellini (12) | NA | NA | 1.12 [0.76, 1.63] p = 0.5552 |
NA | 0.80 [0.57, 1.12] p = 0.2029 |
0.55 [0.37, 0.81] p = 0.0024 |
NA | NA | NA |
| KOSUKE UEDA (13) | NA | NA | 6.518 [1.857, 21.416] p = 0.0048 |
1.21 [0.46, 3.34] p = 0.6981 |
NA | NA | NA | NA | NA |
| Anne Schett (14) | NA | 1.13 [0.50, 2.54] p = 0.78 |
3.45 [1.44, 8.29] p < 0.01 |
0.68 [0.41, 1.14] p = 0.14 |
7.06 [2.55, 19.5] p < 0.01 |
4.24 [1.66, 10.8] p < 0.01 |
3.86 [2.28, 6.53] p < 0.01 |
1.71 [0.81, 3.62] p = 0.16 |
1.36 [0.17, 10.6] p = 0.77 |
| Chirayu Mohindroo (15) | NA | NA | 0.95 [0.74, 1.22] p = 0.68 |
1.04 [0.82, 1.33] p = 0.73 |
NA | NA | NA | NA | NA |
| Arielle Elkrief (16) | NA | NA | 0.32 [0.13, 0.83] p = 0.02 |
0.93 [0.52, 1.63] p = 0.79 |
NA | NA | NA | NA | NA |
| L. Derosa-1 (17) | NA | NA | 2.20 [1.3, 3.3] p = 0.02 |
1.2 [0.8, 1.8] p = 0.43 |
NA | NA | NA | NA | NA |
| L. Derosa-2 (17) | 1.4 [1.0, 1.9] p = 0.05 | NA | 1.4 [1.0, 2.0] p = 0.04 |
1.2 [0.9, 1.6] p = 0.2 |
NA | NA | NA | NA | NA |
| NADINA TINSLEY (18) | 0.880 p = 0.436 |
NA | 1.564 p = 0.003 |
1.001 p = 0.940 |
NA | NA | NA | NA | NA |
| Hyunho Kim (19) | NA | NA | 1.948 [1.31, 2.89] p = 0.001 |
NA | 1.723 [0.78, 3.85] p = 0.181 |
1.165 [0.55, 2.49] p = 0.693 |
1.001 p = 0.891 |
1.115 [0.72, 1.74] p = 0.631 |
1.043 [0.59, 1.83] p = 0.884 |
F, female; M, male; HR, hazard ratio; NA, not available; ECOG PS, Eastern Cooperative Oncology Group performance status.